Physician profile
David P Chamberlain
NPI 1861423071
$7,777.58
in general payments reported to CMS, 2019-2025
35 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $650 · 2021: $799 · 2022: $1,104 · 2023: $1,314 · 2024: $1,683 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,103 · Education: $44.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,103.49 |
| Education | $44.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,606.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,011.03 | 2019-2025 | Evenity, Repatha, Repatha |
| Pfizer INC. | $819.76 | 2019-2025 | |
| Abbvie INC. | $802.09 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $645.14 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $551.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $541.48 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $270.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $193.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $171.76 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $133.89 | 2019-2022 | |
| Allergan, INC. | $94.62 | 2019-2020 | |
| Medtronic, INC. | $81.49 | 2021-2025 | Minimed 780g, Inceptiv |
| Bayer Healthcare Pharmaceuticals INC. | $76.81 | 2023-2025 | |
| Dexcom, INC. | $75.80 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $70.62 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $67.38 | 2019-2025 | Camzyos |
| Exact Sciences Corporation | $65.84 | 2023-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $65.59 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.92 | 2022 | |
| Abiomed | $41.28 | 2025 | |
| Xeris Pharmaceuticals, INC. | $41.22 | 2022-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $38.77 | 2019-2021 | |
| Mylan Specialty L.P. | $36.39 | 2019-2021 | |
| Lundbeck LLC | $33.53 | 2024 | Rexulti |
| Corcept Therapeutics | $33.37 | 2025 | Korlym |
| Senseonics, Incorporated | $27.00 | 2019 | |
| Inspire Medical Systems, INC. | $20.10 | 2025 | Inspire |
| Biohaven Pharmaceuticals, INC. | $18.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.46 | 2025 | Caplyta |
| Kyowa Kirin, INC. | $16.29 | 2025 | |
| Abbott Laboratories | $15.80 | 2021 | |
| Harmony Biosciences LLC | $14.38 | 2020 | |
| Astellas Pharma US INC | $14.16 | 2021 | |
| Esperion Therapeutics, INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.